RxDoctor Payments Data

Charles Guardia, MD

Neurology · Danbury, CTNPI 1841464641

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 45.0% of the total. That places this record below the midpoint for neurology clinicians in CT, where the typical reported total is $893.

$235in general payments, 2019–2025

Across 11 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$106
  • Lilly USA, LLC$89
  • Currax Pharmaceuticals LLC$23
  • Portola Pharmaceuticals, LLC$18
$64,206in research payments, 2019–2025

Across 32 payments — averaging $2006.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$64K

What the payments were for

  • Food & beverage$235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$235 in reported general payments places this provider in the 30th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$156,706
Medicare patients
467
Services billed
1,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl12$182,894
BriviactBrivaracetam18$21,660
Lacosamide34$6,405
Gabapentin171$5,018
ZonisadeZonisamide12$4,541
Levetiracetam95$4,094
Carbidopa-LevodopaCarbidopa/Levodopa129$3,639
Memantine Hcl30$2,841
Entacapone17$2,537
Carbamazepine ErCarbamazepine29$2,525
Divalproex Sodium30$2,376
Lamotrigine53$1,484
Pyridostigmine Bromide18$1,312
Modafinil20$1,036
AmantadineAmantadine Hcl22$811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$89$21214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 280 neurology providers in Connecticut.

Other neurology in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →